Registre des cancers de Loire-Atlantique-Vendée, Nantes, France; Réseau Francim, Toulouse, France.
Breast. 2013 Oct;22(5):810-6. doi: 10.1016/j.breast.2013.02.009. Epub 2013 Mar 6.
Waiting times are key indicators of a health's system performance, but are not routinely available in France. We studied waiting times for diagnosis and treatment according to patients' characteristics, tumours' characteristics and medical management options in a sample of 1494 breast cancers recorded in population-based registries. The median waiting time from the first imaging detection to the treatment initiation was 34 days. Older age, co-morbidity, smaller size of tumour, detection by organised screening, biopsy, increasing number of specimens removed, multidisciplinary consulting meetings and surgery as initial treatment were related to increased waiting times in multivariate models. Many of these factors were related to good practices guidelines. However, the strong influence of organised screening programme and the disparity of waiting times according to geographical areas were of concern. Better scheduling of diagnostic tests and treatment propositions should improve waiting times in the management of breast cancer in France.
等待时间是医疗体系绩效的关键指标，但在法国并未常规提供。我们研究了在基于人群的登记处记录的 1494 例乳腺癌样本中，根据患者特征、肿瘤特征和医疗管理选择，诊断和治疗的等待时间。从第一次影像学检测到治疗开始的中位等待时间为 34 天。多变量模型显示，年龄较大、合并症、肿瘤较小、通过有组织的筛查检测、活检、切除标本数量增加、多学科咨询会议以及作为初始治疗的手术与等待时间延长有关。这些因素中有许多与良好实践指南有关。然而，有组织的筛查计划的强烈影响以及根据地理位置的差异导致的等待时间不均仍然令人担忧。更好地安排诊断测试和治疗建议应能改善法国乳腺癌管理中的等待时间。
